drugset
drugset / Trial / NCT05254613

A Study of Single and Multiple SC Doses of ALXN1830 in Healthy Adult Participants

NCT05254613 ↗

Phase 1 Terminated 12 enrolled Alexion Pharmaceuticals, Inc.
RandomizedParallel-groupDouble-blindBasic science

Summary

This study will evaluate the effects of single ascending doses (SAD) and multiple ascending doses (MAD) of ALXN1830 administered subcutaneously (SC) to healthy adult participants.

Timeline

Start
2019-11-12
Primary completion
2021-01-22
Completion
2021-01-22

Outcome

Outcome not reported

Stopped: “The justification of the early termination of the trial: the study is early terminated due to the Coronavirus 2019 epidemic.”

Drugs

EvaluationDrugModalityDoseRoute
Subject ORILANOLIMAB Monoclonal antibody 300 mg Subcutaneous
Subject ORILANOLIMAB Monoclonal antibody 750 mg Subcutaneous
Subject ORILANOLIMAB Monoclonal antibody 1500 mg Subcutaneous
Subject ORILANOLIMAB Monoclonal antibody 2250 mg Subcutaneous

Indications

No indication recorded.